Skip to content

Author

Dilpreet Singh

We have 1 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review 2026

Emerging trends in nanomedicine: The role of RNAi-based therapies and onpattro’s clinical journey

Onpattro, the first FDA-approved RNAi therapy, is highlighted, Onpattro’s clinical development is highlighted, compares delivery platforms, discusses translational challenges, and emerging technologies that will guide the next generation of RNAi nanomedicines in personalized therapy are examined.

Dilpreet Singh, Satvir Singh, Nitin Tandon et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.